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A Novel State Funded Program to Increase Cord Blood
Collections for Public Banking
Geralyn Annett. Stem Cell Program, UC Davis Medical Center,
Sacramento, CA
The Umbilical Cord Blood Collection Program (UCBCP),
administered by UC Davis Health System, is a new statewide
public program designed to capture the genetic diversity of
Californians through collection of cord blood units (CBUs) for
unrelated transplantation. This program is funded with
revenue from California state birth certiﬁcate fees. The vision
for the implementation of the mission by UCBCP is to expand
access to cord blood stem cells by targeting current inventory
deﬁciencies to provide greater probabilities that people of
any race or ethnicity will ﬁnd an appropriately matched CBU
in the National Cord Blood Inventory (NCBI). In support of
these goals, the UCBCP plans to promote targeted education
programs for health professionals and to utilize best prac-
tices for cord blood collections. Through this process UCBCP
will facilitate the provision of high quality CBUs for trans-
plantation, as well as promote research and development of
effective treatments utilizing cord blood stem cells by
making the CBUs collected that do not meet the criteria for
banking available to researchers.
Much progress has been made toward developing a sustain-
able cord blood collection program for the state over the ﬁrst
year. The UCBCP leadership team has been developed andwe
have identiﬁed cord blood banks through an RFP bidding
process that will be partnered with hospitals in various parts
of the state. The UCBCP is in varying stages of contract
negotiations with three of the public banks who responded
to the RFP. To date negotiations are in place for California
collections in Southern California to occur at ﬁve Scripps
hospitals, funded in part by the UCBCP; and by collections set
to begin at 13 Kaiser Hospitals, also with support from the
UCBCP. In the Central Valley, a collection site is being
developed in Fresno, at the Community Regional Medical
Center. In the Bay area the UCBCP is in negotiations with
several hospitals, including California Paciﬁc Medical Center
and Alta Bates. In the Sacramento area, the UCBCP has
commitments from 2 hospitals and are seeking the same
from two additional birthing centers. At UCDHS, we have
received IRB approval for the program, and have now initi-
ated cord blood collections for purposes of collector training
and process validation.
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CB is a viable alternative source of allogeneic HSC for the
treatment of malignant and non-malignant disease (Cairo et
al BBMT 2008, Szabolcs/Cairo et al Sem in Hem 2010). NK cells
play a role in innate and adaptive immunity and are char-
acterized as CD56+ cell population. Cytotoxic CD56+dim cells
make up 90% of PB NK populations (Shereck/Cairo PBC 2007).
We previously ex-vivo expanded CB MNC into various
phenotypes of CD56+dim and +bright NK cells (Ayello/Cairo
BBMT 2006; Exp. Hematology 2009). NK cell anti-leukemic
and anti-rejection activities may be essential to the interplay
between GVT effects and GVHD after haploidentical HSCT
(Dunbar et al, Haematologica, 2008).
Objective: To determine differential expression, immuno-
phenotype and genomic and proteomic signatures in CB vs
PB CD56+dimNK cells.
Methods: CB NK CD56 cells (94% enrichment) isolated using
a standardkit (MiltenyiBiotec)andsorted intoCD3-/CD56bright
and CD3-/CD56dim subsets. NKR expression was measured by
ﬂow-cytometry. Isolated RNA from CB and PB CD56+dimcells
underwent microarray studies (Affymetrix, U133A_2).
(Agilent GeneSpring and Ingenuity pathway analyses, IPA).
Proteomic performed by LC MS/MS with iTRAQ labeling and
analyzed with SEQUEST, ProteinProphet, and INTERACT.
Results: There was no difference in NKR expression of CD16,
KIR2DL1, KIR2DS1, KIR2DL2, CD161, NKG2C, NKp44, and
NKp46 in CB vs. PB CD56dim. There was a signiﬁcant differ-
ence in CB vs PB CD56+dim NK cells in gene expression
including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11
(4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell
development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34
(3.5F), CD55 (2.1F), CCL13 (2.2F). Further, there was a signif-
icant change in protein expression, CB vs PB CD56+dimcells
over 35 proteins, including CELSR1 (25.0F), BLM (25.0F),
BDNF (20.0F), PKD1 (16.7F), NOTCH2 (16.7F), BIRC2 (12.5F),
AIFM1 (12.5F), EP400 (5.3F), PBX1 (3.9F), SIRT2 (2.9F), LETM1
(2.9F), and ESR2 (2.4F). qRT-PCR and Western blot analysis
validated the genomic and proteomic results, respectively.
Conclusion: These results suggest that CB vs PB CD56+dim NK
cells are more prone to undergo programmed cell death
(apoptosis), over expression of numerous pro-apoptotic
genes, and may be earlier in development (pro-NK) with
signiﬁcant over expression of CD34.467
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Background: Given DCBT may improve engraftment &
protect against relapse, we have adopted DCBT for both
children & adults with acute leukemia, myelodysplasia
(MDS), & myeloproliferative diseases (MPD). However,
determinants of disease-free survival (DFS) after DCBT have
yet to be established.
Methods: We analyzed the DFS of 92 DCBT recipients with
acute leukemia in morphologic remission or aplasia (n¼ 83),
& MDS/MPD with  5% blasts at work-up (n ¼ 9) trans-
planted from 10/2005-5/2012. Nearly all patients had high-
risk disease.
Results: Children [n ¼ 27, median age 7 years (range 0.9-15),
medianweight 30 kg (range 8-72)] were 33% European & 26%
CMV sero-positive with diagnoses of AML (or biphenotypic)
in 44%, ALL in 52%, MDS/MPD in 4%, & all received high-dose
conditioning. Their grafts had a median infused TNC x 107/kg
of 4.4 (larger unit) & 2.9 (smaller unit), & 4% of units were 6/6
HLA-A,-B antigen,-DRB1 allele matched, 61% 5/6, & 35% 4/6.
Adults [n ¼ 65, median age 47 years (range 16-69), median
weight 69 kg (range 45-105)] were 48% European & 68% CMV
sero-positive. Diagnoses in adult patients were AML (or
biphenotypic) in 62%, ALL in 26%, & MDS/MPD in 12%. Forty-
two percent of adults received high-dose & 58% reduced
intensity conditioning. Their units had a median infused
TNC/kg of 2.7 & 2.0, respectively, & 3% were 6/6 HLA-
matched, 44% 5/6, & 53% 4/6. All patients received
calcineurin-inhibitor/mycophenolate mofetil immunosup-
pression. Sustained donor neutrophil engraftment was seen
in 93% of children (median neutrophil recovery at 20 days) &
97% of adults (median 25 days). Platelet engraftment was
seen in 85% of children (median recovery at 50 days) & 83% of
adults (median 48 days). The incidence of day 180 grade II-IV
acute GVHD was 41% in children & 60% in adults. Day 100
TRM was 7% in children & 15% in adults. The 2-year relapse
incidence was 17% in children & 7% in adults. With a median
33month (range 3-84) follow-up of survivors, the 2-year DFS
is 72% in children & 65% in adults. Univariate analysis of
variables potentially inﬂuencing 2-year DFS (Table 1)
demonstrated there were no differences according to patient
age, ancestry, remission status, conditioning intensity,
engrafting unit-recipient HLA-match, or engrafting unit
infused TNC dose/kg. However, patients who were CMVTable 1
Comparison 2-Year DFS P value
Age 0-15 years (n ¼ 27) 72% 0.29
>16 years (n ¼ 65) 65%
Ancestry Europeans (n ¼ 40) 69% 0.90
Non-Europeans (n ¼ 52) 66%
Remission Status CR1 (n ¼ 49) 65% 0.92
All others (n ¼ 43) 69%
Conditioning
Intensity
High-dose (n ¼ 54) 70% 0.50
Reduced intensity (n ¼ 38) 62%
Recipient CMV
Sero-status
CMV+ (n ¼ 51) 53% 0.01
CMV- (n ¼ 41) 81%
Engrafting Unit -
Recipient
HLA-match
4/6 (n ¼ 36) 74% 0.96
5-6/6 (n ¼ 51) 69%
2-6/10 (n ¼ 50) 69% 0.87
7-9/10 (n ¼ 37) 72%
Engrafting Unit
Infused TNC dose
< 3.0  107/kg (n ¼ 62) 72% 0.90
 3.0 x 107/kg (n ¼ 25) 68%seronegative had a higher 2-year DFS (81% vs 53%, P ¼ .01).
Multivariate analysis revealed recipient CMV serostatus was
a predictor of DFS independent of patient age, & its effect was
mediated by an inﬂuence on TRM.
Conclusions: DCBT can achieve high & comparable DFS in
both European & non-Europeanpatients with acute leukemia
with a low rate of relapse. While the mechanism of the
mortality risk associated with CMV seropositivity requires
further investigation, our ﬁndings support DCBT as an
immediate alternative therapy for high-risk acute leukemia in
patients without suitable unrelated volunteer donors.468
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The association between HLA-DP and hematopoietic stem
cell transplantation (HCT) outcomes is still questionable. In
the present study, we examined 80 patients who underwent
ﬁrst allogeneic HCT between the years of 2005-2008 and
were followed up for at least 2 years post transplant. These
patients were 10/10 matched for HLA-A, -B, -C, -DR and -DQ
at high resolution using Sequence Speciﬁc Priming (SSP) and/
or Sequence Based Typing (SBT). We analyzed the impact of
donor/recipient (D/R) mismatches at HLA-DPA1 and HLA-
DPB1 on different HCT outcomes including aGVHD, cGVHD,
and risk of disease relapse in a single center study. Addi-
tionally, we classiﬁed HLA-DPB1 mismatches as permissive
or non-permissive according to a previously described TCE4
algorithm and attempted to conﬁrm its efﬁcacy. Each cate-
gorical testing variable were compared with the different
clinical end points by 2-tailed Fischer's exact test. The
magnitude of effect was estimated by risk ratios and their
95% conﬁdence intervals. “p” value 0.05 (two-sided) was
considered signiﬁcant. A total of 160 alleles were observed at
HLA-DPA1 and 159 alleles were observed at HLA-DPB1 locus.
HLA-DPA1 and DPB1 allelic frequencies in the study pop-
ulationwere not signiﬁcantly different from those previously
observed in other Caucasian populations. At DPA1 locus, D/R
mismatching was observed in 15% of D/R pairs, however
almost all of them were mismatched at the level of single
allele. Since only one patient was mismatched for both DPA1
alleles, the effect of DPA1 mismatches were not analyzed for
single or double mismatches. At the DPB1 locus, 44% D/R
pairs were found mismatched, including 24% for single allele
and 20% for both alleles. No variables analyzed (allelic or
non-permissive mismatches) were signiﬁcantly associated
with any transplant outcomes evaluated in this patient
cohort. Our study did not conﬁrm the association between
HLA-DP mismatches and HCT outcomes. The TCE4 algorithm
also did not yield signiﬁcant advantageous results. Our
results are in accord with a recent French study but dis-
concordant with various studies conducted elsewhere,
including the United States and the United Kingdom. Further
molecular study of HLA-DP in the clinical setting is war-
ranted to further elucidate the role of this gene and its mis-
matching on HCT outcome.
